Published : 05 Jun 2024, 15:33

‘Papilovax’, a cervical cancer vaccine: A great revolution by Incepta Pharmaceuticals Limited

Incepta Pharmaceuticals Limited is a reputable pharmaceutical company in Bangladesh that specializes in manufacturing generic drugs and vaccines. Recently, they have made a significant contribution to healthcare by inventing an effective vaccine for preventing cervical cancer. 

In 2022, Incepta Pharmaceuticals invented 'Papilovax', a revolutionary vaccine that works by preventing Human papillomavirus (HPV), the primary cause of cervical cancer. 

The vaccine is available in suspension form for injection in a prefilled syringe, which should be administered intramuscularly.

Women aged between 9 to 45 years are advised to take this vaccine, which requires three doses. The second dose needs to be taken after two months, and the third dose should be taken after six months. 

The vaccine's price is 2500 taka.


Cervical cancer is the second most common cancer among women aged between 15 to 44 years in Bangladesh. 

According to the World Health Organization's prediction, approximately 505,703 women in Bangladesh will die from cervical cancer by the year 2070. 

The lack of screening, early marriages, early initiation of sexual activities, sexually transmitted diseases, and low socio-economic conditions are responsible for the prevalence of cervical cancer in Bangladesh.

We are hopeful that Incepta Pharmaceutical's great invention will help prevent cervical cancer and significantly contribute to Bangladesh's healthcare system.

Image Source:

https://inceptavaccine.com/

Fighting Cancer Desk
Fighting Cancer Desk